Saframycins, analogues and uses thereof

Details Saframycins, analogues and uses thereof Saframycins, analogues and uses thereof

2001-11-05

2004-10-26

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S342000

Reexamination Certificate

active

06809099

ABSTRACT:

BACKGROUND OF THE INVENTION
The discovery of novel therapeutic agents has traditionally relied on the identification of biologically active secondary metabolites of microorganisms. These compounds have provided a rich source of natural products that have either been utilized directly as effective therapeutic agents, or have provided leads for novel therapeutic agents to be developed through synthetic techniques.
One disease for which the development of novel therapeutics is particularly important is cancer, which not only has eluded a “cure”, but is also one of the leading disease-related causes of death of the human population. Examples of anticancer agents that have been identified from or developed from natural sources include paclitaxel, mitomycin C, and adriamycin to name a few. One drawback to the use of secondary metabolites from natural resources, however, has been that these agents are generally only present in minute quantities. Fortunately, in an effort to make these agents more available for use, and to enable further pharmaceutical research, synthetic chemists have developed elegant and efficient synthetic strategies to enable the production of either the natural products themselves, or useful derivatives thereof.
Although these therapeutic agents, and others developed from natural sources, through the efforts of synthetic chemistry, are currently in use for the treatment of individuals having cancer, many of these agents, as well as other common treatments such as surgery and radiation, are often unselective for tumor cells and/or are so toxic as to render the individual significantly immunocompromised. Thus, although many strides have been made in the development of novel treatments, there remains a need for the identification of additional therapeutics, preferably those that are more selective and less toxic.
One particular family of natural products that has generated significant interest is the saframycins. The saframycins are a class of antibiotics with activity against gram-positive bacteria and also against several kinds of tumor. Specifically, several saframycin analogues have been isolated and characterized in recent years (see, DE 2839668; U.S. Pat. Nos. 4,248,863; 4,372,947; 5,023,184; 4,837,149; and EP 329606). For example saframycins A-H, R and S have been isolated from the culture broths of
Streptomyces lavendulae
, and saframycins M
x1
and M
x2
, have been isolated from the culture broths of the myxobacterium,
Myxococcus xanthus
, each of the saframycins varying in the oxidation state of the ring system and in substitution of the core structure (see, for example, Saito et al.
Chem. Pharm. Bull.
1995, 43, 777). It has been suggested that certain saframycins, namely A and C exhibit extreme cytotoxicity toward culture cells and toward several experimental tumors including leukemias L1210 and P388 and Ehrlich carcinoma. Specifically, saframycin A has been shown to block RNA synthesis in cultured cells, and it has been suggested that saframycins A and C exhibit this potency because of their ability to bind and cleave DNA (for a discussion of the biological activity of saframycins see, for example, Lown et al.
Biochemistry
1982, 21, 419; Ishiguro et al.
Biochemistry
1978, 17, 2545; Rao et al.
Chem. Res. Toxicol
1990, 3, 262; Ishiguro et al
J Biol. Chem.
1981, 256, 2162). Although this class of natural products has shown promising biological activity, there have been few investigations into the synthesis and development of novel analogues of this family of natural products (see, EP 233841; EP 173649; Fukuyama et al.
J. Am. Chem. Soc.
1982, 104, 4957-4958; Kubo et al.
J. Org. Chem.
1988, 53, 4295-4310; Fukuyama et al.
J. Am. Chem. Soc.
1990, 112, 3712-3713).
Clearly, there remains a need to further investigate the potential of this class of natural products, and analogues thereof, to develop novel, more potent and more selective therapeutics. Additionally, because of the complexity of the structure of this class of natural products, there also remains a need to develop additional synthetic techniques to rapidly access novel compounds based upon the general core structure of the saframycins, and other related compounds.
SUMMARY OF THE INVENTION
In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof.
The present invention additionally provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.


REFERENCES:
patent: 4248863 (1981-02-01), Arai
patent: 4372947 (1983-02-01), Arai et al.
patent: 4837149 (1989-06-01), Arai et al.
patent: 5023184 (1991-06-01), Reichenbach et al.
patent: 5721362 (1998-02-01), Corey et al.
patent: 5834228 (1998-11-01), Becker et al.
patent: 6124292 (2000-09-01), Corey
patent: 6124293 (2000-09-01), Rinchart et al.
patent: 6316214 (2001-11-01), Rinchart et al.
patent: 6348467 (2002-02-01), Corey
patent: 6569859 (2003-05-01), Corey
patent: 28 39 668 (1979-03-01), None
patent: 0 173 649 (1985-08-01), None
patent: 0 233841 (1987-12-01), None
patent: 0 329 606 (1989-02-01), None
patent: 56-135486 (1981-10-01), None
patent: 57-50896 (1982-03-01), None
patent: 61-58593 (1986-03-01), None
patent: 63-2991 (1988-01-01), None
patent: WO 98/12198 (1998-03-01), None
patent: WO 00/18233 (2000-04-01), None
patent: WO 00/69862 (2000-11-01), None
patent: WO 01/19824 (2001-03-01), None
patent: WO 01/53299 (2001-07-01), None
patent: WO 01/87894 (2001-11-01), None
patent: WO 01/87895 (2001-11-01), None
Arai, et al., “Increased Production of Saframycin A and Isolation of Saframycin S”,the Journal of Antibiotics,XXXIII (9): 951-960, 1980.
Arai, Directed Biosynthesis of New Saframycin Derivatives with Resting Cells of Streptomyces Lavendulae,Antimicrobial Agents and Chemotherapy,28(1): 5-11, 1985.
Bodian et al., “Inhibition of Fusion-Inducing Conformational Change of Influenza Hemagglutinin by Benzoquinones and Hydroquinones”,Biochemistry,32:2967-2978, 1993.
Davidson, B., “Renieramycin G, A New Alkaloid from the Sponge Xestospongia Caycedoi”,Tetrahedron Letters,33(26): 3721-3724, 1992.
Eisen, et al., “Binding of the Influenza A Virus to Cell-Surface Receptors: Structures of Five Hemagglutinin-Sialyloligosaccharide Complexes Determined by X-Ray Crystallography”,Virology,232:19-31, 1997.
Ekambareswara, et al., “DNA Sequence Selectivities in the Covalent Bonding of Antibiotic Saframycins Mx1, Mx3, A, and S Deduced from MPE-Fe(II) Footprinting and Exonuclease III Stop Assays”,Biochemisry,31: 12076-12082, 1992.
Ekambareswara, et al., “Mode of Action of Saframycin Antitumor Antibiotics: Sequence Selectivities in the Covalent Binding of Saframycins A and S to Deoxyribonucleic Acid”,Chem. Res. Toxicol.3:262-267, 1990.
Evans, et al., “Stereoselective Synthesis of (±)-Cyanocycline”,J. Am. Chem. Soc.108: 2478-2479, 1986.
Flanagan, et al., “Synthetic Studies on Quinocarcin: Total Synthesis of (±)-Quinocarcinamide Via Dipole Cycloaddition of an Azomethine Ylide Generated by NPS Oxidation”,J. Org. Chem.60: 6791-6797, 1995.
Fukuyama, et al., “Total Synthesis of (±)-Saframycin A”,J. Am. Chem. Soc.112: 3712-3713, 1990.
Fukuyama, et al., “Stereocontrolled Total Sunthesis of (±)-Saframycin B”,J. Am. Chem. Soc.,104: 4957-4958, 1982.
Fukuyama, et al., A Stereocontrolled Total Synthesis of (±)-Renieramycin A,Tetrahedron Letters,31(42): 5989-5992, 1990.
Ha, et al., X-Ray Structures of H5 Avian and H9 Swine Influenza Virus Hemagglutinins Bound to Avian and Human Receptor Analogs,PNAS,98(20): 11181-11186, 2001.
Hoffman, et al., “Structure-Based Identification of an Inducer of the Low-pH Conformational Change in the Influenza Virus Hemagglutinin: Irreversible Inhibition of Infectivity”,Journal of Virology,71(11)

Affiliated with

Also associated with

Rating

Saframycins, analogues and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Saframycins, analogues and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Saframycins, analogues and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3291971